Outrun Therapeutics Targets HPV Cancers with Novel Drug Strategy

DUNDEE, Scotland – March 17, 2026 – In a significant move for oncology, biotech firm Outrun Therapeutics has announced its lead therapeutic program, a first-of-its-kind drug strategy aimed at HPV-positive head and neck cancer. The company also unveiled a powerhouse Scientific Advisory Board (SAB) stacked with world-renowned experts, signaling strong confidence in its novel approach to fighting the disease.

Outrun's lead candidate is a small-molecule inhibitor designed to block a cellular enzyme called E6AP. This strategy, developed using the company's proprietary XL discovery platform, has shown strong preclinical results and is on track to enter clinical trials in 2027. The announcement marks a major milestone for the company and offers new hope for a growing patient population facing difficult treatment options.

"Outrun's mission is to develop protein stabilising therapeutics to treat disease, and the selection of our lead programme, for the treatment of HPV positive head and neck cancer, is an important milestone in our journey," said Dr. Tony Johnson, Board Chair and Interim CEO of Outrun Therapeutics. "This is a massively underserved patient population, and we are confident that our novel approach to protein stabilisation offers a breakthrough route to bringing meaningful treatments to those in need."

A New Strategy: Restoring the Body's Natural Defenses

At the heart of Outrun's innovation is a fundamentally different approach to cancer therapy. Many targeted treatments focus on destroying harmful proteins. Outrun aims to do the opposite: stabilize a crucial protective protein that the human papillomavirus (HPV) cleverly disables.

In HPV-driven cancers, the virus's E6 oncoprotein essentially hijacks a cellular enzyme, the E3 ubiquitin ligase known as E6AP. This rogue complex then tags the body's most important tumor suppressor, p53, for destruction. With the p53 "guardian" eliminated, cancerous cells can grow unchecked. Outrun's strategy is to inhibit E6AP, breaking the chain of command. By blocking E6AP, the drug is designed to prevent p53's degradation, allowing it to accumulate and restore its natural tumor-suppressing function, potentially causing cancer cells to die off.

This protein stabilization method is a novel frontier in a field that has been heavily focused on targeted protein degradation. The company's ability to rapidly identify such a specific inhibitor is credited to its proprietary XL discovery platform, which has been used to screen over 45 different E3 ligases for therapeutic potential across oncology, neurology, and cardiovascular diseases.

Answering an Urgent and Growing Unmet Need

While often associated with a better prognosis than their HPV-negative counterparts, HPV-positive head and neck cancers present a significant and growing health challenge. The incidence is rising, particularly among younger patients. Current standard-of-care treatments, including aggressive surgery, radiation, and chemotherapy, can be effective but often leave patients with severe, life-altering side effects, including difficulty swallowing, speaking, and long-term pain.

This creates an urgent unmet need for more targeted and less toxic therapies. Outrun's approach, which specifically targets a mechanism unique to HPV-infected cancer cells, holds the promise of a more precise treatment with potentially fewer off-target effects. The market for HPV-related cancers is substantial, projected to surpass $14 billion by 2031, reflecting the scale of the problem and the commercial potential for a breakthrough therapy.

A 'Dream Team' of Scientific Validation

Perhaps the most striking aspect of Outrun's announcement is the formation of its Scientific Advisory Board, a move that provides immense validation for its technology. The board reads like a who's who of cancer biology and drug development.

Crucially, the SAB includes Professor Martin Scheffner of the University of Konstanz, a molecular biologist who co-discovered the very mechanism Outrun is targeting: the role of E6AP in degrading p53 in HPV-infected cells. His involvement lends unparalleled credibility to the scientific foundation of the program. He is joined by Professor Gigi Lozano of the MD Anderson Cancer Center, a world-leading authority on the p53 tumor suppressor pathway itself.

Bridging the gap from lab to clinic are two of the world's foremost experts in head and neck cancer: Professor Kevin Harrington from the Institute of Cancer Research and Professor Glenn Hanna from the Dana-Farber Cancer Institute. Their deep clinical and translational expertise will be vital in designing trials and navigating the path to patient application. Rounding out the group is Dr. Donald Ogilvie, a drug discovery veteran with two decades of experience at AstraZeneca, who brings invaluable insight into the complexities of developing and commercializing new cancer therapeutics.

Professor Satpal Virdee, Outrun's Founder and Chair of the SAB, highlighted the significance of this assembly. "Attracting such high-profile and experienced figures to our SAB is tremendous validation of the novel nature of our technology, and we are grateful for their commitment," he stated. "Their expertise will be invaluable as we develop the translational strategy, clinical design, and biomarker validation to support our goal of establishing efficacy and differentiation in the HPV-induced head and neck cancer field, and transition to a clinical stage company."

Backed by a $10 million seed round from leading life-science investors M Ventures and MP Healthcare Venture Management, Outrun Therapeutics is now poised to advance its lead program toward a development candidate later this year. The convergence of a novel scientific platform, a clear clinical need, robust financial backing, and an unparalleled team of experts positions the Scottish biotech as a significant new player in the fight against cancer.